Sagida Bibi

Employment

• University of Oxford

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (30)

• Dosing interval is a major factor determining the quality of T cells induced by SARS-CoV-2 mRNA and adenoviral vector vaccines
  Science Immunology 2025 DOI: 10.1126/sciimmunol.adu4610
  +Save
• MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines
  Ali Amini, Lucy C. Garner, Robert H. Shaw +75 more
  Science Immunology 2025 DOI: 10.1126/sciimmunol.adu3337
  +Save
• Safety and humoral immunogenicity of the ChAdOx1 nCoV-19 vaccine administered as a fourth dose booster following two doses of ChAdOx1 nCoV-19 and a third dose of BNT162b2 (COV009): A prospective cohort study
  Journal of Infection 2025 DOI: 10.1016/j.jinf.2025.106423
  +Save
• AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific T H 1 response with a diverse TCR repertoire
  Science Translational Medicine 2021 DOI: 10.1126/scitranslmed.abj7211
  +Save
• Highly-Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe Polymerase Chain Reaction
  2021 DOI: 10.1101/2021.11.01.21265384
  +Save
• Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
  2021 DOI: 10.1101/2021.06.21.21258528
  +Save
• A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.
  Alain Townsend, Pramila Rijal, Julie Huiyuan Xiao +60 more
  Nature communications 2021 DOI: 10.1038/s41467-021-22045-y
  +Save
• Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2
  2021 DOI: 10.1101/2021.03.12.435194
  +Save
• Antibody evasion by the P.1 strain of SARS-CoV-2
  Cell 2021
  +Save
• Antibody evasion by the P.1 strain of SARS-CoV-2.
  Wanwisa Dejnirattisai, Daming Zhou, Piyada Supasa +48 more
  Cell 2021 DOI: 10.1016/j.cell.2021.03.055
  +Save
• Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
  Katherine R. W. Emary, Tanya Golubchik, Parvinder K. Aley

  +62 more

  • Cristina V. Ariani
  • Brian Angus
  • Sagida Bibi
  • Beth Blane
  • David Bonsall
  • +57 more
  Lancet (London, England) 2021 DOI: 10.1016/s0140-6736(21)00628-0
  +Save
• Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers
  2021 DOI: 10.1101/2021.03.19.436030
  +Save
• Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.
  Daming Zhou, Wanwisa Dejnirattisai, Piyada Supasa +41 more
  Cell 2021 DOI: 10.1016/j.cell.2021.02.037
  +Save
• Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.
  Piyada Supasa, Daming Zhou, Wanwisa Dejnirattisai +50 more
  Cell 2021 DOI: 10.1016/j.cell.2021.02.033
  +Save
• Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
  2021 DOI: 10.2139/ssrn.3777268
  +Save
• Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
  Merryn Voysey, Sue Ann Costa Clemens, Shabir Ahmed Madhi +97 more
  Lancet (London, England) 2021 DOI: 10.1016/s0140-6736(21)00432-3
  +Save
• Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
  2021 DOI: 10.2139/ssrn.3779160
  +Save
• Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
  Jordan R. Barrett, Sandra Belij‐Rammerstorfer, Christina Dold +97 more
  Nature medicine 2020 DOI: 10.1038/s41591-020-01179-4
  +Save
• Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
  Merryn Voysey, Sue Ann Costa Clemens, Shabir Ahmed Madhi +97 more
  Lancet (London, England) 2020 DOI: 10.1016/s0140-6736(20)32661-1
  +Save
• T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
  Katie Ewer, Jordan R. Barrett, Sandra Belij‐Rammerstorfer +97 more
  Nature medicine 2020 DOI: 10.1038/s41591-020-01194-5
  +Save